The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
The liquid biopsy era is finally here.
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.